ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
elbarto
|
44 |
14K |
4 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
14K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
elbarto
|
44 |
14K |
4 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
14K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
elbarto
|
44 |
14K |
4 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
14K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
elbarto
|
44 |
14K |
3 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
44
|
14K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce gearing up for Indonesian trials
|
|
elbarto
|
13 |
4.4K |
7 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
13
|
4.4K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce gearing up for Indonesian trials
|
|
elbarto
|
13 |
4.4K |
10 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
13
|
4.4K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
elbarto
|
38 |
10K |
2 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
elbarto
|
38 |
10K |
3 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
elbarto
|
53 |
13K |
4 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
53
|
13K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
elbarto
|
53 |
13K |
2 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
53
|
13K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Safety Committee Approves Expansion of Ph I/II DFI Trial
|
|
elbarto
|
27 |
6.1K |
2 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
27
|
6.1K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Establishes Strategic Partnership in South-East Asia
|
|
elbarto
|
48 |
12K |
4 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
48
|
12K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Establishes Strategic Partnership in South-East Asia
|
|
elbarto
|
48 |
12K |
7 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
48
|
12K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
elbarto
|
15 |
4.8K |
0 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
15
|
4.8K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
elbarto
|
15 |
4.8K |
1 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
15
|
4.8K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
elbarto
|
34 |
12K |
4 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
34
|
12K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
|
|
elbarto
|
32 |
10K |
7 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
32
|
10K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
|
|
elbarto
|
13 |
3.3K |
10 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
13
|
3.3K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
How do you get access to Recce 327
|
|
elbarto
|
17 |
6.0K |
14 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
17
|
6.0K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Entitlement Offer - Announcement of Results
|
|
elbarto
|
13 |
5.5K |
9 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
5.5K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Placement and Entitlement Offer
|
|
elbarto
|
101 |
34K |
1 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
101
|
34K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Placement and Entitlement Offer
|
|
elbarto
|
101 |
34K |
1 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
101
|
34K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Placement and Entitlement Offer
|
|
elbarto
|
101 |
34K |
3 |
25/09/23 |
25/09/23 |
ASX - By Stock
|
101
|
34K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Placement and Entitlement Offer
|
|
elbarto
|
101 |
34K |
3 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
101
|
34K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Becoming a substantial holder
|
|
elbarto
|
18 |
5.7K |
7 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
18
|
5.7K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Becoming a substantial holder
|
|
elbarto
|
18 |
5.7K |
1 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
18
|
5.7K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Becoming a substantial holder
|
|
elbarto
|
18 |
5.7K |
5 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
18
|
5.7K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Need to push the IV dose higher
|
|
elbarto
|
26 |
10K |
4 |
12/09/23 |
12/09/23 |
ASX - By Stock
|
26
|
10K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Placement and Entitlement Offer
|
|
elbarto
|
101 |
34K |
14 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
101
|
34K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
elbarto
|
66 |
17K |
2 |
10/09/23 |
10/09/23 |
ASX - By Stock
|
66
|
17K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
elbarto
|
66 |
17K |
0 |
10/09/23 |
10/09/23 |
ASX - By Stock
|
66
|
17K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
elbarto
|
66 |
17K |
2 |
10/09/23 |
10/09/23 |
ASX - By Stock
|
66
|
17K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4E and Unaudited Preliminary Report
|
|
elbarto
|
20 |
6.2K |
2 |
02/09/23 |
02/09/23 |
ASX - By Stock
|
20
|
6.2K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Additional Positive Patient Cases - Special Access Scheme
|
|
elbarto
|
24 |
7.4K |
12 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
24
|
7.4K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II Burn Wound Infection Trial Stage 1 Complete
|
|
elbarto
|
16 |
6.0K |
3 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
16
|
6.0K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II Burn Wound Infection Trial Stage 1 Complete
|
|
elbarto
|
16 |
6.0K |
0 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
16
|
6.0K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
elbarto
|
124 |
40K |
16 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
124
|
40K
|
16
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
elbarto
|
124 |
40K |
26 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
124
|
40K
|
26
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
elbarto
|
45 |
13K |
2 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
45
|
13K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Clarification - 5x Higher Concentration in Urine & Plasma
|
|
elbarto
|
21 |
5.7K |
11 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
21
|
5.7K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Clinical Trial Data Review Complete
|
|
elbarto
|
31 |
8.1K |
2 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
31
|
8.1K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
|
|
elbarto
|
35 |
16K |
10 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
35
|
16K
|
10
|
|
ASX - By Stock
|
WDS |
Re:
News: WDS Australia's Woodside Energy reports fatality at North Rankin complex
|
|
elbarto
|
8 |
4.9K |
14 |
03/06/23 |
03/06/23 |
ASX - By Stock
|
8
|
4.9K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: DFI Clinical Trial Outpatient Nurses Appointed
|
|
elbarto
|
26 |
10K |
5 |
29/05/23 |
29/05/23 |
ASX - By Stock
|
26
|
10K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: WA Government Sponsorship for BIO Korea 2023
|
|
elbarto
|
16 |
7.0K |
3 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
16
|
7.0K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: WA Government Sponsorship for BIO Korea 2023
|
|
elbarto
|
16 |
7.0K |
2 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
16
|
7.0K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: WA Government Sponsorship for BIO Korea 2023
|
|
elbarto
|
16 |
7.0K |
11 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
16
|
7.0K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Up strongly on no news
|
|
elbarto
|
41 |
15K |
3 |
21/04/23 |
21/04/23 |
ASX - By Stock
|
41
|
15K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Up strongly on no news
|
|
elbarto
|
41 |
15K |
1 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
41
|
15K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
|
|
elbarto
|
35 |
16K |
5 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
35
|
16K
|
5
|
|